Shepherd Center — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$126,596	1
2023	Research	$247,693	3
2021	Research	$510,117	57
2020	Research	$209,357	29
2019	Research	$765,368	28

Breakdown

Who paid Research payments · program years 2019–2024

Genentech, Inc. $735,848 58 payments
Biogen, Inc. $542,998 4 payments
Novartis Pharmaceuticals Corporation $374,290 4 payments
Roche Products Limited $86,035 16 payments
F. Hoffmann-La Roche AG $79,835 27 payments
AbbVie, Inc. $32,339 5 payments
GW Research Limited $7,108 1 payment
Boston Scientific Corporation $680 3 payments

Studies the money was for Research payments · program years 2019–2024

Ensemble $473,249 44 payments
A Study to Evaluate Efficacy, Safety, and Tolerability of 6-Week Extended Interval Dosing of Natalizumab (BG00002) in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) Switching From Treatment With 4-Week Natalizumab Standard Interval Dosing (SID) in Relation to Continued SID Treatment $464,645 1 payment
AGNOS: An 18-month, Open-label, Multi-Center Study to Assess the Effect of Ofatumumab 20mg SC Monthly in Treatment Nave, Very Early Relapsing Remitting Multiple Sclerosis Patients Benchmarked Against Healthy Controls on Select Outcomes $374,290 4 payments
Assessing Disease Activity in Minority Patients With Relapsing Multiple Sclerosis Using Ocrelizumab $262,599 14 payments
Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment $86,035 16 payments
Ocrelizumab in Patients With RMS $79,835 27 payments
Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS) $74,920 1 payment
A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Traumatic Cervical Spinal Cord Injury $32,339 5 payments
Gwsp18023 $7,108 1 payment
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants $2,903 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.